Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.

Pediatric blood & cancer - 1 Jul 2017

Finkelstein Yaron, Blonquist Traci M, Vijayanathan Veena, Stevenson Kristen E, Neuberg Donna S, Silverman Lewis B, Vrooman Lynda M, Sallan Stephen E, Cole Peter D

Abstract excerpt

BACKGROUND: Bone fractures and osteonecrosis frequently complicate therapy for childhood acute lymphoblastic leukemia (ALL). Bone toxicity has been associated with exposure to corticosteroids and methotrexate (MTX) and age greater than 10 years. We tested whether common genetic polymorphisms were associated with bone toxicity during treatment for ALL. PROCEDURE: A total of 615 of 794 children enrolled on Dana...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Asparaginase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Fractures, Bone

Share to Methotrexate

Share to Osteonecrosis

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Thymidylate Synthase

Source

Identifiers

PMID: 27957785
DOI: 10.1002/pbc.26393

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.PMID 27957785Read ↗

Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With LeukemiaSemantic proximity Read ↗

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.Semantic proximity Read ↗

Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.Semantic proximity Read ↗

Association of thymidylate synthase 5'-UTR 28bp tandem repeat and serine hydroxymethyltransfarase C1420T polymorphisms with susceptibility to acute leukemia.Semantic proximity Read ↗

Severe toxicities in amazonian populations and the role of precision medicine in acute lymphoblastic leukemia treatment.Semantic proximity Read ↗

Genetic factors contributing to late adverse musculoskeletal effects in childhood acute lymphoblastic leukemia survivors.Semantic proximity Read ↗

Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study.Semantic proximity Read ↗

Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.